Madrigal Pharmaceuticals (MDGL) Current Leases (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 15 years of Current Leases data on file, last reported at $1.7 million in Q1 2026.

• Current Leases for Q1 2026 came in at $1.7 million, up 67.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 67.03% YoY), and the FY2025 annual result was $1.0 million, up 3.56% from the prior year.
• Current Leases rose to $1.7 million in Q1 2026 per MDGL's latest filing, from $1.0 million in the prior quarter.
• Over five years, Current Leases peaked at $1.7 million in Q1 2026 and troughed at $411000.0 in Q2 2023.
• A 5-year average of $798882.4 and a median of $760000.0 in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2023: Current Leases surged 118.11% in 2022, then slumped 53.24% in 2023.
• A 5-year view of Current Leases shows it stood at $602000.0 in 2022, then fell by 12.46% to $527000.0 in 2023, then soared by 86.53% to $983000.0 in 2024, then increased by 3.56% to $1.0 million in 2025, then soared by 66.7% to $1.7 million in 2026.
• Business Quant data shows MDGL's Current Leases at $1.7 million in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.